Gastroenterology

Gastroenterology

Volume 113, Issue 3, September 1997, Pages 1042-1043
Gastroenterology

A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease

https://doi.org/10.1016/S0016-5085(97)70205-1Get rights and content

Abstract

This article has no abstract. To view the article, select the "View Print Version (PDF)" link above.

References (0)

Cited by (14)

  • Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives

    2001, American Journal of Gastroenterology
    Citation Excerpt :

    The mean CDAI scores did not differ significantly in placebo and infliximab-treated patients at 8 wk. Stated in more conventional terms, approximately 30% of infliximab-treated patients were in clinical remission (p = 0.074 by Fisher’s exact test, as compared with placebo patients) and 50% of infliximab-treated patients had a clinical response (decrease in CDAI of ≥70 points) by 2 wk after infusion (79). These results are comparable to those described for pooled-dose remission (27–42%) or response (61–68%) rates at 2 wk after infusion in the major efficacy trials of infliximab (Table 1).

  • The role of tumor necrosis factor in the pathophysiology of heart failure

    2000, Journal of the American College of Cardiology
    Citation Excerpt :

    By contrast, excessive activation of TNF alpha or nontissue specific expression leads to tissue necrosis and apoptosis. Indeed, recent studies have demonstrated a causative role for TNF alpha in a group of diseases including: septic shock, rheumatoid arthritis (26), preeclampsia (27), hemolytic uremic syndrome (28), allograft rejection (29)and regional enteritis (30). The first recognition that TNF alpha might participate in the development of congestive heart failure (CHF) came in 1990 when Levine et al. (31)demonstrated that circulating levels of TNF alpha were elevated in patients with end stage heart failure and cachexia.

View all citing articles on Scopus
View full text